title: Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey.
abstract: We have studied the pharmacokinetics of dehydroepiandrosterone (DHEA) administered orally (PO), i.v., and during a continuous i.v. infusion in ovariectomized cynomolgus monkeys under suppression of adrenal DHEA secretion with dexamethasone. The glucocorticoid induced a rapid suppression of serum cortisol, DHEA, and DHEA-sulfate (DHEA-S) as well as their metabolites, thus permitting to use this model to study the pharmacokinetic parameters of DHEA and its metabolites without significant interference by endogenous steroid levels. After a single 10 mg i.v. dose of DHEA, the metabolic clearance rate and terminal half-life of DHEA were 99.9 +/- 9.1 liter/d and 4.5 +/- 0.3 h, respectively. Following a 50-mg DHEA PO dose, systemic availability was only 3.1 +/- 0.4%. As shown by their high conversion ratios, the major circulating metabolites of DHEA are DHEA-S, androsterone glucuronide, and androstane-3 alpha,17 beta-diol-glucuronide. The conversion ratios of androst-5-ene-3 beta,17 beta-diol, testosterone, dihydrotestosterone, and androstenedione are, in comparison, small. No transformation to estrogens could be detected in the circulation after either i.v. or PO DHEA administration. The present data indicate that DHEA is transformed predominantly into androgens in peripheral tissues in ovariectomized cynomolgus monkeys with minimal (androgens) or no (estrogens) release of the bioactive steroids in the circulation. Furthermore, the present study supports the importance of measuring circulating androgen glucuronide derivatives to assess hormonal exposure of peripheral tissues to androgens after DHEA administration.
authors.affiliation: Molecular Endocrinology and Oncology Research Center, Laval University Medical Center,Centre Hospitalier de l'Université Laval and Laval University, Québec, Canada G1V 4G2.
authors.forename: Mathias
authors.initials: M
authors.lastname: Leblanc
authors.forename: Claude
authors.initials: C
authors.lastname: Labrie
authors.forename: Alain
authors.initials: A
authors.lastname: Bélanger
authors.forename: Bernard
authors.initials: B
authors.lastname: Candas
authors.forename: Fernand
authors.initials: F
authors.lastname: Labrie
mesh_terms: D000284:Administration, Oral; D000305:Adrenal Cortex Hormones / Q000097:blood / Q000378:metabolism; D000728:Androgens / Q000097:blood; D000818:Animals; D001682:Biological Availability; D003687:Dehydroepiandrosterone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019314:Dehydroepiandrosterone Sulfate / Q000097:blood; D003907:Dexamethasone / Q000494:pharmacology; D004967:Estrogens / Q000097:blood; D005260:Female; D007275:Injections, Intravenous; D008252:Macaca fascicularis; D010052:Ovariectomy
chemical_list: D000305:Adrenal Cortex Hormones; D000728:Androgens; D004967:Estrogens; D003687:Dehydroepiandrosterone; D019314:Dehydroepiandrosterone Sulfate; D003907:Dexamethasone